No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Hainan Haiyao Subsidiary Gains Approval for Fengliao Stomach Health Tablet License
Chinese Stocks Closes Week With Gains on Ongoing DeepSeek Popularity; Daan Gene Soars 10%
Hainan Haiyao Unit's Flufenidone Capsules Placed in Drug Regulator's Breakthrough Drug List; Shares Up 3%
Hainan Haiyao: 2024 Annual Results Forecast
Further Weakness as Hainan Haiyao (SZSE:000566) Drops 6.7% This Week, Taking Five-year Losses to 26%
Hainan Haiyao Co., Ltd.'s (SZSE:000566) Popularity With Investors Is Under Threat From Overpricing
